Fast Glycan Sequencing Using a Fully Automated Carbohydrate Sequencer

Similar documents
The Importance of Temperature Control in Capillary Electrophoresis of Carbohydrates

Assessing Glycosimilarity of Biotherapeutics

Repeatability of C100ht Biologics Analyzer, for High Throughput Glycan Screening

High-Throughput Glycan Screening to Remove Biopharmaceutical Development Bottlenecks

Automating the C100ht Biologics Analyzer Sample Preparation on a Biomek i5 Liquid Handler Platform

Simplifying CE-SDS Data Processing

Fully Automated C100HT Biologics Analyzer Sample Preparation on a Biomek i5 Multichannel Workstation

Improving the Detection Limits for Highly Basic Neuropeptides Using CESI-MS

Separation of Recombinant Human Erythropoietin (rhepo) using the European Pharmacopoeia Method on the PA 800 plus Pharmaceutical Analysis System

Rediscover the Strengths of Your PA 800 Plus - A Multi-Attribute Protein Analyzer

Rapid magnetic bead based sample preparation for automated and high throughput N-glycan analysis of therapeutic antibodies

The Ludger GX-mAb Glycoprofiling Service High Throughput glycan analysis service of monoclonal antibodies (mabs) for drug developers and manufacturers

More Samples. Better Decisions Faster.

IgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup

Automated and quantitative analysis of biologics

Analysis of Monoclonal Antibody Charge Variants by Capillary Zone Electrophoresis

Automated and Quantitative Analysis of Biologics

Detecting Challenging Post Translational Modifications (PTMs) using CESI-MS

N-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF

Impurity Detection with a New Light Emitting Diode Induced Fluorescence Detector Coupled to the Agilent 7100 Capillary Electrophoresis System

A Robust cief Method: Intermediate Precision for the ph 5-7 Range

mab Glycopeptide Profiling with V-Tag Adding reliable glycoprofiling to your peptide mapping workflow with ease and simplicity

Microchip Electrophoresis for Glycoprotein Separation. Analytical Strategy, September 30th, 2014 Karina Hasler & Adrian Müller

Isotopic Resolution of Chromatographically Separated IdeS Subunits Using the X500B QTOF System

Unified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis

Capillary Electrophoresis in Quality Control PART II: CE-SDS: Method Development and Robustness

Capillary Electrophoresis Compendial Applications

Answers, Simple and Streamlined. Solutions for Biotherapeutic Intact Mass Analysis

Automated and quantitative

Optimization of cief to Resolve Challenging MAb Samples of Clinical Immunodiagnostic Relevance

"VUPNBUFE BOE RVBOUJUBUJWF

OptiFlow Quant Solution for High-Sensitivity Quantitation

BioBA High Capacity Enrichment Sample Preparation Kit:

deltadot ANTIBODY ANALYSIS Application Note: Antibodies using LABEL FREE INTRINSIC IMAGING LONDON United Kingdom

Application Note. Abstract. Author. Biopharmaceutical

Eoin F.J. Cosgrave, Matthew A. Lauber, Robert Birdsall, and Sean M. McCarthy Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION

Assay of IgG Purity and Heterogeneity using High-Resolution Sodium Dodecyl Sulfate Capillary Gel Electrophoresis

Application Note. Authors. Abstract. Biopharmaceuticals

Disulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column

Universal Solution for Monoclonal Antibody Quantification in Biological Fluids Using Trap-Elute MicroLC-MS Method

Accelerate mab Characterization Using Automated Sample Prep

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis

Separation of Native Monoclonal Antibodies and Identification of Charge Variants:

APPLICATION INFORMATION

Analysis of Intact Monoclonal Antibodies Using an M3 MicroLC with the TripleTOF 6600

High Performance Analytics for Bioprocessing and Manufacturing

Application Note # ET-20 BioPharma Compass: A fully Automated Solution for Characterization and QC of Intact and Digested Proteins

Rapid Identification and Characterization of Biologics using CESI 8000-TripleTOF MS Platform

Improving characterization of monoclonal antibodies

Charge Variant Assessment of Nanobodies at the Intact Level by CESI-MS

Monoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column

PA 800 plus Catalog. Systems/Software

Assessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients

Background - Importance of monoclonal antibody characterization

A universal chromatography method for aggregate analysis of monoclonal antibodies

3D Structure of Biologics in a Convenient Immunoassay Format

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography

Improving Sensitivity for an Immunocapture LC-MS Assay of Infliximab in Rat Plasma Using Trap-and-Elute MicroLC-MS

Clone Selection Using the Agilent 1290 Infinity Online 2D-LC/MS Solution

Evaluation of chromatographic phases for separation of differentially labeled glycans from erythropoietin and trastuzumab

Ultra-Sensitive Quantification of Trastuzumab Emtansine in Mouse Plasma using Trap-Elute MicroLC MS Method

In Vitro Glycoengineering - Its Application and Effect on IgG1

Lifetime stability of size exclusion chromatography columns for protein aggregate analysis

Application Note. Biopharm. Author. Abstract. Christian Wenz Agilent Technologies, Inc. Waldbronn, Germany

Biotherapeutic Peptide Mapping Information Dependent Acquisition (IDA) Method

LIFluor EnhanCE. for use with dsdna 1000 and dsdna 20,000 Kits

Biochromatography Bring more Zen into your life and laboratory

NanoLC-Ultra system. data sheet. Introducing the NanoLC-Ultra family of high pressure HPLCs for proteomics research

Chromatography column for therapeutic protein analysis

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs

Improving Sensitivity in Bioanalysis using Trap-and-Elute MicroLC-MS

Characterize Fab and Fc Fragments by Cation-Exchange Chromatography

High-Resolution Separation of Intact Monoclonal Antibody Isoforms

SCIEX Anion Analysis Kit For P/ACE MDQ and P/ACE MDQ plus Capillary Electrophoresis Systems. Instruction Guide

Sean M. McCarthy and Martin Gilar Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL RESULTS AND DISCUSSION

Agilent AssayMAP Bravo Platform AUTOMATED PROTEIN AND PEPTIDE SAMPLE PREPARATION FOR MASS SPEC ANALYSIS

Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product ICH Guidance

Cell Clone Selection Using the Agilent Bio-Monolith Protein A Column and LC/MS

New techniques for extraction, separation, and detection of EPO Dr. Zhen Liu

Antibody Analysis by ESI-TOF LC/MS

The United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts

Pharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study

Capillary Electrophoresis of Proteins

Monosaccharide and Sialic Acid Determinations in Biosimilars Using HPAE-PAD

TECHNICAL INFORMATION

A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies

Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q TOF

Biosimilar Profiling Application Note NT-PR-010

ACCURACY THE FIRST TIME. Bring Your Esoteric Assays In-House Routinely SCIEX DIAGNOSTICS MASS SPECTROMETERS

Quantification of Host Cell Protein Impurities Using the Agilent 1290 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System

FOR RESEARCH USE ONLY STORE AT -20 C

Seamless Method Transfer from an Agilent 1260 Infinity Bio-inert LC to an Agilent 1260 Infinity II Bio-inert LC

Biotherapeutic Non-Reduced Peptide Mapping

Comparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing

Monoclonal Antibody Charge Variants Identification by Fully Automated Capillary Isoelectric Focusing Mass Spectrometry

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider

ph gradient analysis of IgG1 therapeutic monoclonal antibodies using a 5 µm WCX column

MAbPac RP Column. High-performance reverse phase chromatography column for monoclonal antibody analysis

Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column

Transcription:

Fast Glycan Sequencing Using a Fully Automated Carbohydrate Sequencer Andras Guttman 1 and Marton Szigeti 2 1 SCIEX Separations, Brea, CA 2 Horváth Csaba Laboratory of Bioseparation Sciences, Debrecen, Hungary Overview Who Should Read This: Senior Scientists, Lab Directors in the biopharmaceutical and biomedical fields. Focus: A new automated glycan sequencing approach for comprehensive structural elucidation of complex carbohydrates. Goal: To demonstrate an automated carbohydrate sequencing solution that significantly decreases manual steps and reduces the analysis time from 1 5 days to 1 2 hours. Problem: Previously, carbohydrate sequencing was a tedious and time-consuming manual process. It required either consecutive addition of the sequencing exoglycosidase enzymes to a single reaction vial, which could take up to a week depending on the number of enzymes used, or arrays (combinations) of enzymes in multiple vials processing multiple sample aliquots in parallel, which could still take a full day. Results: Using automated sample and enzyme handling, as well as optimized reaction times and temperatures for the individual exoglycosidase reactions, the SCIEX PA 800 Plus Pharmaceutical Analysis System dramatically reduces hands-on steps and provides carbohydrate sequencing in just 1 2 hours. Key Challenges: Current carbohydrate sequencing methods are based on manual processing that can take from one day to a full week. Key Features: The precise temperature control of the sample storage compartment in the PA 800 Plus System provides proper incubation conditions for the carbohydrate sequencing reactions The separation capillary serves a dual role, functioning both as the separation column and as a reagent (enzyme) delivery device The PA 800 Plus Pharmaceutical Analysis System Intelligent instrument control optimizes and automates the sequencing process The Fast Glycan Labeling and Analysis Kit vastly simplifies sample preparation and speeds glycan characterization Introduction Monoclonal antibodies (mabs) are one of the fastest emerging groups within the rapidly growing protein therapeutics market. In most instances, mabs possess a conserved N-linked glycosylation site in each of the CH2 domains of the Fc portion of the heavy chain, but may also have additional sugar structures attached to the Fab domains. 1 Increasing evidence shows that these carbohydrate moieties play important roles in biological activity, physicochemical properties, and effector functions. 2 Even minor changes in the carbohydrate structures (linkage, position, and site occupancy) can influence bioactivity. For example, IgG molecules with identical amino acid sequences can gain 50- fold efficacy in terms of antibody-dependent cellular cytotoxicity (ADCC) when the core fucose residue is absent in the conserved Fc glycan. 3 Terminal sialic acids, on the other hand, transform monoclonal antibodies into anti-inflammatory mediators capable of suppressing autoantibody-mediated inflammation. Due to this sensitivity to changes in carbohydrate structures, fast, efficient, p1

and reliable bioanalytical techniques are needed along the entire pharmaceutical processing pipeline, from clone selection to lot release. 4 The extremely high diversity of protein glycosylation makes structural elucidation challenging. In most instances, only a combination of analytical methods can provide the desired information. 5 The most frequently used methods for structural analysis of complex carbohydrates include capillary electrophoresis (CE), nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and high-performance liquid chromatography (HPLC), often combined with exoglycosidase digestion techniques. Capillary electrophoresis with laser-induced fluorescent detection (CE-LIF) is a high-resolution bioanalytical tool with excellent sensitivity. It is capable of rapid, comprehensive profiling of complex carbohydrates, even discriminating between closely related positional and linkage isomers. 5 Individual glycan structures, corresponding to peaks in the electropherogram, can be proposed based on their glucose unit (GU) values. 6 However, due to the high diversity of possible glycan structures, existing GU databases might not contain the glycan structures at hand. Carbohydrate sequencing can alleviate this handicap by providing required structural identification. 7 N-linked carbohydrate sequencing starts with the release of the sugar moieties from the polypeptide backbone of the glycoprotein, in most cases using peptide-n4-(n-acetylbeta-glucosaminyl) asparagine amidase (PNGase F). For capillary electrophoresis-based N-linked carbohydrate profiling, the liberated oligosaccharides are labeled with a charged p2 Figure 1. Exoglycosidase digestion reaction pathways of the major sugar residues of interest in monoclonal antibody N-glycans. Structure numbers correspond to the peak numbers in Figure 2 in the Results section of this note. N-glycan nomenclature and symbolic representations use the notation previously suggested by Harvey et al. 9 : sialidase; : galactosidase; : hexosaminidase.

fluorophore, 8-aminopyrene-1,3,6-trisulfonic acid (APTS), and separated by CE-LIF. In cases when the glycan structures in the sample are not found in the GU database, carbohydrate sequencing is necessary to identify the components. Current carbohydrate sequencing strategies involve use of specific exoglycosidase enzymes to remove the sugar residues from the non-reductive end of the glycan structures. The enzymes can be used serially, or arrays (combinations) of enzymes can be applied in a parallel fashion. 7 In both instances, following the reaction steps the resulting glycan pools are analyzed by CE-LIF and the migration time shifts of all the peaks are recorded. Glycan sequencing starts with cutting the out-most sugars from the non-reducing end (in most instances sialic acids), followed by removal of all galactose and N-acetylhexosamine residues (including antennary and bisecting) until the trimannosyl-chitobiose core structure of all N-linked sugars is reached (fucosylated and/or non-fucosylated). This enzyme reaction sequence is represented in Figure 1. If antennary specification is needed, linkage specific mannosidases (1-3 or 1-6) can be applied. 8 For serial exoglycosidase-based sequencing, enzymes are added to the same reaction vial individually in series. Each reaction step takes approximately 16 hours at 37 C. Using the parallel approach, on the other hand, specific arrays (combinations) of enzymes are prepared in an equal number of sample vials. 10 In the case of monoclonal antibody N-glycans, the first vial would contain sialidase, the second vial sialidase and galactosidase, and the third vial sialidase, galactosidase, and hexosaminidase. Sample aliquots are processed concurrently in each vial. For the same set of exoglycosidases, this parallel approach requires only 16 hours for the reactions to reach completion. This note presents semi-automated (use of exoglycosidase arrays) and fully automated (serial exoglycosidase addition) carbohydrate sequencing strategies that take advantage of the unique hardware features of the PA 800 Plus Pharmaceutical Analysis System to accomplish the sequencing task in only 1 2 hours. The method works without the need to isolate any of the individual structures from the initial glycan pool. GU values are used to calculate the mobility shifts for full structural elucidation. Experimental Chemicals Human immunoglobulin G (IgG), acetonitrile, and sodium cyanoborohydride (1 M in THF) were obtained from Sigma Aldrich (St. Louis, MO). PNGase F, sialidase A (α2 3,6,8,9), jack bean β-galactosidase (β1 3,4,6) and jack bean β-n-acetylhexosaminidase (β1 2,3,4,6) were obtained from New England Biolabs (Ipswich, MA). Glycan Release and Labeling Following the protocol of the Fast Glycan Sample Preparation and Analysis Kit (Part Number B94499PTO, SCIEX, Brea, CA), 100 µg of IgG1 was: 1. Denatured 2. Digested by PNGase F (2.5 mu) 3. Labeled with fluorophore (8-aminopyrene-1,3,6-trisulfonate, APTS) 4. Purified using magnetic beads 5. Eluted in deionized water Sequencing Digestion The exoglycosidase digestion-mediated sequencing reactions were accomplished in the temperature-controlled sample storage compartment of the PA 800 Plus System. The compartment temperature was set between 40 C and, according to requirements of the enzyme reactions. Temperature drop during the tray movement (sample in and out) was less than 4 C and re-equilibration took only a few minutes. Exoglycosidase digestions were performed by the addition of: 5.0 mu sialidase (1.0 µl) 25 mu β-galactosidase (1.0 µl) 25 mu β-n-acetyl-hexosaminidase (1.0 µl) to 50 µl of glycan sample-containing reaction mixture in a premixed array form (semi-automated carbohydrate sequencing) or in a step-by-step fashion (fully automated carbohydrate sequencing). Since therapeutic monoclonal antibodies usually do not possess any antennary fucosylation, only sialidase, β-galactosidase and β-n-acetyl-hexosaminidase were used in the reactions. p3

Semi-automated carbohydrate sequencing The semi-automated carbohydrate sequencing workflow is depicted in Table 1. The workflow utilized four reaction vials, all containing the APTS-labeled IgG1 glycans, and three corresponding enzyme arrays. The first vial contained only IgG1 glycans and served as the control. Arrays of exoglycosidases were added to the three other vials: Vial 1: IgG1 glycans only (control) Vial 2: IgG1 glycans + sialidase Vial 3: IgG1 glycans + sialidase and β-galactosidase Vial 4: IgG1 glycans + sialidase, β-galactosidase, and β-n-acetyl-hexosaminidase The four vials were placed into the sample tray and incubated in the storage compartment at. Sequencing / Separation Steps CE-LIF analysis of IgG1 pool Sialidase digestion CE-LIF analysis after sialidase digestion Galactosidase digestion CE-LIF analysis after galactosidase digestion Hexosaminidase digestion CE-LIF analysis after hexosaminidase digestion Elapsed Time 12 24 36 48 60 Table 1: Timing of the semi-automated carbohydrate sequencing workflow. Fully automated carbohydrate sequencing The fully automated carbohydrate sequencing workflow is depicted in Table 2. This workflow required only one reaction vial. The analytical capillary was used to deliver the appropriate exoglycosidases to the vial. Nanovials (SCIEX), each containing 5.0 µl of one exoglycosidase, were placed in the outlet buffer tray of the PA 800 Plus System. Similar to the semi-automated approach, first the APTS-labeled IgG1 pool sample was analyzed by CE-LIF. After this separation step, the capillary was rinsed with water and, by careful adjustment of the inlet pressure, used to deliver 1 µl of sialidase enzyme to the sample vial. The temperature of the sample storage compartment was ramped from 40 C to during the 16 minute sialidase incubation step. Upon finishing the sialidase digestion, the reaction mixture was injected into the capillary, which was filled with separation gelbuffer while digestion was taking place, and analyzed by CE-LIF. Next, the capillary was rinsed again with water followed by the capillary delivery of 1 µl of β-galactosidase into the sample vial. This reaction mixture was incubated for 32 minutes at, and then injected for analysis into the capillary. This process was repeated for the β-n-acetyl-hexosaminidase (1 µl), and after 32 min incubation at the reaction mixture were injected and analyzed by CE-LIF. Capillary Electrophoresis All capillary electrophoresis separations were performed on a PA800 Plus Pharmaceutical Analysis System with laser-induced fluorescence detection (SCIEX). Column: 20 cm effective length (30 cm total, 50 µm ID) bare fused silica capillary (EZ-CE cartridge) Separation gel buffer: HR-NCHO Separation temperature: 25 C Separation voltage: (0.17 min ramp time), E=1000 V/cm p4

Sequencing / Separation Steps CE-LIF analysis of IgG pool Sialidase digestion CE-LIF analysis after sialidase digestion Galactosidase digestion CE-LIF analysis after galactosidase digestion Hexosaminidase digestion CE-LIF analysis after hexosaminidase digestion Elapsed Time 12 28 40 72 84 116 128 40 Table 2: Timing of the fully automated carbohydrate sequencing workflow. Polarity: Reversed (cathode at injection side, anode at detection side). Injection steps: 1. Water at 3.0 psi for 5.0 sec 2. Sample at 1.0 kv for 1.0 sec 3. Bracketing standard (DP2 + DP15) at 1.0 kv for 1.0 sec Detection: laser-induced fluorescence (488 nm excitation / 520 nm emission) Data acquisition and analysis were done using the 32 Karat software (version 10.1, SCIEX). GU values were assigned for all peaks after each sequencing step. Results IgG1 samples were processed and analyzed using both the semi-automated and fully automated carbohydrate sequencing workflows. After completion of each digestion step, the resulting reaction products were analyzed by CE-LIF and identified by the GU value and GU value shifts of the affected peaks (Table 3). The type and linkage information of the sugar residue losses were determined by the exoglycosidase enzyme used. The number of the residues was determined by the extent of the GU shifts. Thus, positional and linkage information were also determined by the actual exoglycosidases in the reaction mixture. Based on the GU shifts, the glycan structures were built up for all sample components after each enzyme was applied and the reaction products were analyzed. 5 Sialidase Digestion GU Shifts Galactosidase Digestion GU Shifts Hexosaminidase Digestion GU Shift Glycan ID 9 11 12 Glycan ID 6 7 Glycan ID 13 Structure FA2(3)G1 FA2G2 FA2BG2 Structure FA2 FA2B Structure F(6)M3 GU Value 9.11 10.16 10.55 GU Value 7.69 8.23 GU Value 6.75 1 FA2G2S2 5.00 5.16 8 FA2(6)G1 8.76 1.07 6 FA2 7.69 0.94 2 FA2BG2S2 5.14 5.41 9 FA2(3)G1 9.11 1.42 7 FA2B 8.23 1.47 3 FA2(3)G1S1 6.04 3.07 10 FA2B(6)G1 9.18 0.95 4 FA2G2S1 6.80 3.37 11 FA2G2 10.16 2.47 5 FA2BG2S1 6.98 3.56 12 FA2BG2 10.55 2.32 Table 3: Identified GU value shifts of the major IgG1 glycans. p3

Semi-Automated Sequencing Results At zero elapsed time, the undigested control sample was analyzed (Figure 2, lower panel), followed by the CE-LIF analysis of the exoglycosidase reaction mixtures after the relevant elapsed times: Sialidase at 12 min (Figure 2A, NANase trace) Sialidase and β-galactosidase at 36 min (Figure 2A, NANase+GALase trace) This semi-automated exoglycosidase array-based sequencing required only 1 hour, including the reaction times, for all enzyme digestions and the CE-LIF separations. However, manual premixing of the exoglycosidase enzyme arrays was required, and four times as much IgG1 sample was required compared to the fully automated workflow. Sialidase + β-galactosidase + β-n-acetyl-hexosaminidase at 48 min (Figure 2A, NANase+GALase+HEXase trace) Figure 2. Automated carbohydrate sequencing of monoclonal antibody N-glycans. Lower panel: CE-LIF trace of the APTS-labeled IgG N-glycan pool. A: exoglycosidase array digestion-based semi-automated glycan sequencing. B: consecutive exoglycosidase digestion-based fully automated glycan sequencing. Fully automated carbohydrate sequencing Similar to the semi-automated approach, in the fully automated workflow the APTS-labeled IgG1 pool sample was analyzed first by CE-LIF (Figure 2, lower panel). The capillary was then rinsed with water and, by careful adjustment of the inlet pressure, used to deliver 1 µl of sialidase enzyme to the sample vial. The sample was incubated according to the automated sequencing workflow outlined in the Experimental section of this note. The digestions products were sampled and analyzed (Figure 2B, NANase trace). The process was repeated with β-galactosidase (Figure 2B, GALase trace) and β-n-acetyl-hexosaminidase Figure 2B, HEXase trace). This fully automated workflow did not require any pre-analysis preparation of reaction arrays, but due to the serial nature of the reactions the total sequencing time was a little more than 2 hours. p4

Conclusion This work introduced the use of the PA 800 Plus Pharmaceutical Analysis System for automated glycan sequencing by CE-LIF. Both semi- and fully automated exoglycosidase digestionbased carbohydrate sequencing were accomplished by using the temperature-controlled sample storage compartment of the CE instrument as a reaction incubation chamber and using the separation capillary both for analysis and as an enzyme delivery device. Through careful optimization of reaction temperatures, enzyme concentrations, and incubation times, sequencing of the monoclonal antibody N-glycans was accomplished in 1 hour using the semi-automated workflow and in a little over 2 hours using the fully automated workflow. Conventional manual carbohydrate sequencing methods require between one day (array-based) and one week (sequential) to accomplish the same task. References 1 Varki, A. et al. Essentials of Glycobiology. 2nd edn, (Cold Spring Harbor Laboratory Press, 2009). 2 Hayes, J. M. et al. Glycosylation and Fc receptors. Curr Top Microbiol Immunol 382, 165-199, (2014). 3 Shade, K. & Anthony, R. Antibody Glycosylation and Inflammation. Antibodies 2, 392-414 (2013). 4 Guttman, A. Bioanalytical Tools for the Characterization of Biologics and Biosimilars. LC.GC Magazine 30 412-421. (2012). 5 Mittermayr, S., Bones, J. & Guttman, A. Unraveling the glyco-puzzle: glycan structure identification by capillary electrophoresis. Anal Chem 85, 4228-4238, (2013). 6 Mittermayr, S. & Guttman, A. Influence of molecular configuration and conformation on the electromigration of oligosaccharides in narrow bore capillaries. Electrophoresis 33, 1000-1007 (2012). 7 Guttman, A. Multistructure sequencing of N-linked fetuin glycans by capillary gel electrophoresis and enzyme matrix digestion. Electrophoresis 18, 1136-1141, (1997). Who is SCIEX? SCIEX company s global leadership and worldclass service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. 8 Szabo, Z. et al. Ultrasensitive capillary electrophoretic analysis of potentially immunogenic carbohydrate residues in biologics: galactose-alpha-1,3-galactose containing oligosaccharides. Mol Pharm 9, 1612-1619, (2012). 9 Harvey, D. J. et al. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9, 3796-3801 (2009). 10 Guttman, A. & Ulfelder, K. W. Exoglycosidase matrixmediated sequencing of a complex glycan pool by capillary electrophoresis. J Chromatogr A 781, 547-554 (1997). Contact Us: sciex.com/contact-us For Research Use Only. Not for use in diagnostic procedures. 2017 AB SCIEX. SCIEX is part of AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX is being used under license. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA. Publication number: RUO-MKT-02-6633-A (2017.09.14.) Headquarters 500 Old Connecticut Path, Framingham, MA 01701, USA Phone 508-383-7800 sciex.com International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices